JPRN-UMIN000036969已完成未知
Phase I/II study of S-IROX as second-line therapy after nab-Paclitaxel + Gemcitabine for unresectable pancreatic cancer - 2nd-line S-IROX Study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Pulmonary fibrosis or interstitial pneumonia Watery stool Infection Uncontrolled diabetes mellitus Any serious complication Pregnancy
研究者
相似试验
招募中
2 期
Phase 2 study of S-IROX as down staging chemotherapy for borderline resectable pancreatic cancerpancreatic cancer(borderline resectable)JPRN-UMIN000033796Department of Hepatobiliary and Pancreatic Oncology/Surgery National Canser Center24
招募中
2 期
BR-SIROXPancreatic cancerJPRN-jRCTs031180263Esaki Minoru24
招募中
4 期
Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedNCT05786989Chongqing University Cancer Hospital32
Unknown
2 期
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine CarcinomaNeuroendocrine CarcinomaNCT03279614Peking University45
招募中
不适用
Phase I/II study of S-1, irinotecan plus oxaliplatin combination therapy (SOXIRI) for advanced pancreatic cancer(KANAPS 06 study)advanced pancreatic cancerJPRN-UMIN000014339KANAPS(Kansai and Nara Pancreatobiliary Study group)53